Knowing who may progress along the disease pathway is critical for early diagnosis and intervention, improved treatment and better disease management, according to a team led by researchers from the ...
Monoclonal Antibody to Inhibit IL33 for Autoimmune Disorders is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders.
Now, scientists at Stanford University have found that a faulty genetic molecule could be responsible for the immune system misidentifying healthy tissue as a threat. The breakthrough study, published ...